27 C
Vientiane
Thursday, May 8, 2025
spot_img
Home Blog Page 623

Stryker launches ProCeed hospital bed

New hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.

PORTAGE, Mich., Feb. 17, 2025 /PRNewswire/ — Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of the ProCeed hospital bed, offering simplicity while enhancing care across various regions.

New ProCeed hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.
New ProCeed hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.

Over the last several years, nursing staff turnover has increased, and a significant percentage of frontline nurses across the globe have considered leaving their roles1. As hospitals continue to face nursing shortages and staff burnout2, patient care equipment, like beds, need to endure a heavy workload and provide staff with a straightforward experience. ProCeed was built to withstand the demands of healthcare and provide staff with a durable and cleanable hospital bed.

“As we designed ProCeed, helping keep clinicians and patients safe while allowing for an efficient and easy-to-use platform was key,” said Scott Sagehorn, vice president and general manager of Stryker’s Acute Care business. “Launching a bed that meets the needs of staff and patients in these markets will help deliver consistent and quality care.”

ProCeed helps keep patients and care teams safe with various design elements, including low bed height, which supports patient mobility and reduces the risk of injury from falls. The fifth wheel, an extra wheel positioned at the core of the bed, reduces start-up push force and offers steering help to reduce the risk of caregiver back injuries. ProCeed also offers two headboard designs, including one that stays stationary as the bed frame tilts, or a mobile headboard that tilts, raises and lowers as the frame articulates into different positions.

To learn more about ProCeed, please visit our website.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com

1: Jester R. Editorial – Global shortage of nurses – Rebecca Jester for May 2023 issue. Int J Orthop Trauma Nurs. 2023 May;49:101018. doi: 10.1016/j.ijotn.2023.101018. Epub 2023 Mar 24. PMID: 37041090; PMCID: PMC10038672.

2: Recover to rebuild: Investing in the Nursing Workforce for Health System Effectiveness – James Buchan and Howard Catton for March 2023 issue. International Council of Nurses. 2023 March;26.

A healthcare professional must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that healthcare professionals be appropriately trained in the use of any particular product before use.

The information presented is intended to demonstrate the breadth of Stryker product offerings. A healthcare professional must always refer to the package insert, product label and/or Instructions for Use before using any Stryker product.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: ProCeed, Stryker. All other trademarks are trademarks of their respective owners or holders.

Media contact
Meghan Menz
Sr. Director, Communications
meghan.menz@stryker.com

 

WSPN Pioneers Stablecoin 2.0 at Consensus Hong Kong 2025

SINGAPORE, Feb. 17, 2025 /PRNewswire/ — WSPN (Worldwide Stablecoin Payment Network) is thrilled to announce its participation in Consensus Hong Kong 2025, marking a significant milestone in the evolution of digital finance. As stablecoins emerge as a transformative force in global finance, with ARK Invest forecasting a $1.4 trillion market by 2030, WSPN is pioneering innovative Stablecoin 2.0 solutions that are reshaping the future of digital payments.

During Consensus Hong Kong on February 19-20, 2025, WSPN will showcase its cutting-edge stablecoin solutions at Booth #2103. Visitors will experience firsthand how WSPN’s technology is driving this trillion-dollar market transformation through more efficient, secure, and transparent payment solutions while ensuring financial stability.

On the eve of the main conference, WSPN, together with industry leaders Solana, RedotPay, and MetaEra, will host an exclusive cocktail reception: “Stable Rise – Stablecoin 2.0: Future of Digital Payment”. This high-profile gathering aims to unite visionaries and innovators who are actively shaping the future of digital payments.

The reception will feature insightful keynote speeches from industry leaders, premium networking opportunities, and discussions on the future of digital payments. Attendees will gain firsthand insights into the technology driving the next trillion-dollar market while exploring partnership opportunities in the rapidly growing Asia Pacific region, solidifying WSPN’s role as a pioneer in the stablecoin ecosystem.

Event Details:

  • WSPN at Consensus Hong Kong 2025: February 19-20, 2025, Booth #2103, Hong Kong Convention and Exhibition Centre
  • “Stable Rise – Stablecoin 2.0: Future of Digital Payment” Cocktail Party: February 18, 6:30 PM – 9:30 PM, Conrad Hong Kong Garden Cafe Terrace. Register here: https://lu.ma/7ebuj5cd

Visit WSPN at Consensus Hong Kong 2025 to discover the future of digital payments through our Stablecoin 2.0 technology. Don’t miss our exclusive cocktail reception to engage with industry leaders and be part of the conversation shaping the future of stablecoins.

About WSPN

WSPN is a leading provider of next-generation stablecoin infrastructure, committed to building a more secure, efficient, and transparent payment solution for the global economy. Their flagship product, WUSD stablecoin, is pegged 1:1 to the U.S. Dollar and aims to optimize secure digital payments for Web3 users. WSPN ‘s Stablecoin 2.0 approach prioritizes user-centricity, community governance, and accessibility, paving the way for widespread stablecoin adoption.

Learn more: www.wspn.io | X | LinkedIn

Moby, a Leading Options Protocol, Expands to Berachain Mainnet

–    Moby’s Strategic Expansion to Scale Institutional-Grade Trading and Structured Products

–    Pioneering Options Innovation: RFA-Selected Moby Enhances Liquidity Berachain’s PoL 

SINGAPORE, Feb. 17, 2025 /PRNewswire/ —  Moby, the No.1 options protocol on Arbitrum with a total trading volume of $3.5 billion, has officially launched on the Berachain Mainnet.

Moby, a Leading Options Protocol, Expands to Berachain Mainnet
Moby, a Leading Options Protocol, Expands to Berachain Mainnet

Berachain is an EVM-identical Layer 1 blockchain that leverages the novel Proof of Liquidity (PoL) consensus mechanism, setting it apart from traditional proof-of-stake (PoS) networks. By embedding liquidity provisioning into its core security model, PoL aligns incentives across validators, applications, and users—ensuring liquidity and security at the network level.

Moby’s pioneering efforts have been recognized through its selection for Berachain’s prestigious Request for Application (RFA) program—an endorsement reflecting the protocol’s robust infrastructure and potential to enhance liquidity across the Berachain ecosystem. Moreover, Moby has secured partnerships with key industry players such as Kodiak, Infrared, PumpBTC and GMX, further solidifying its position within the ecosystem.

Moby offers two key advantages for Berachain traders and institutions: deeper liquidity and exceptionally tight spreads, both designed to ensure an optimal trading environment. Meanwhile, liquidity providers benefit from high passive income, underpinned by stable risk management achieved through real-time automatic hedging.

Additionally, Moby’s Structured Product Vault (SPV) seamlessly integrates with Berachain’s PoL mechanism, providing an efficient yield-enhancing solution. The SPV aggregates PoL rewards and optimizes their yield through algorithmic options trading. It will integrate LST/LRT and Real World Assets (RWA) to expand the on-chain options market.

“The expansion to Berachain is a pivotal step for Moby,” stated Ben, CEO of Moby. “By leveraging Berachain’s PoL model, we are setting the stage for a more liquid and scalable on-chain options market—ushering in a new era of institutional-grade trading and structured products”

Coinciding with its official launch on the Berachain mainnet, Moby introduced an incentive program for early access users. This initiative allows users to earn rewards based on their engagement.

Moby Contacts

Team Moby
team@moby.trade

About Moby

Moby is an on-chain options protocol to lead the next narrative for DeFi. Moby offers an optimized trading environment based on its pioneering SLE (Synchronized Liquidity Engine) and Dynamic Risk Premium model, which enables real-time accurate pricing, narrowest spread in the market, abundant liquidity, and Robinhood-class UI/UX.

Moby is set to provide new features such as capital efficiency improvement models and structured products to welcome institutions and the traditional TradFi audience.

 Website  Twitter  Discord  Docs  Blog  Telegram

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S.

At the World Conference on Lung Cancer (WCLC) in September 2024, IBI363 presented promising efficacy signals in patients with sqNSCLC who had previously received immunotherapy:

  • In the 3 mg/kg dose group, among patients with at least 12 weeks of follow-up or study completion (n=18), the objective response rate (ORR) was 50.0%, and the disease control rate (DCR) was 88.9%. The median progression-free survival (PFS) has not yet been reached and remains under follow-up.
  • In the 1/1.5 mg/kg dose group, the median PFS was 5.5 months (95% CI: 1.5, 8.3), with a 12-month PFS rate of 30.7%, highlighting the potential long-term benefits of immunotherapy.
  • Across the 1/1.5/3 mg/kg dose groups, patients with PD-L1 TPS<1% (n=22) and those with PD-L1 TPS≥1% (n=22) achieved encouraging ORRs of 36.4% and 31.8%, respectively, suggesting IBI363's potential advantage in PD-L1 low-expression populations.

Dr. Hui Zhou, Senior Vice President of Innovent, stated, “We are pleased that IBI363 has been granted Fast Track Designation by the FDA for sqNSCLC, following its previous designation for melanoma. Earlier, we reported that in an expanded cohort of sqNSCLC patients, IBI363 showed a trend toward improved ORR and DCR at higher doses, along with a manageable safety profile. The latest PFS data from the 3 mg/kg dose group after longer follow-up further strengthens our confidence in IBI363’s potential as an immunotherapy offering long-term benefits to patients. We will present the relevant data at upcoming academic conferences this year. More encouragingly, IBI363 has demonstrated potent anti-tumor activity regardless of PD-L1 expression levels. This suggests that IBI363 may not only advance treatment for immunotherapy-resistant populations but also for cold tumors with low or no PD-L1 expression. In addition to lung cancer, we have observed encouraging efficacy signals in cold tumors, including colorectal cancer and mucosal melanoma, with melanoma already advancing to pivotal clinical stages. Moving forward, we will continue to explore IBI363 in early-line treatment and in combination therapies.”

Fast Track Designation (FTD) is a regulatory process designed to expedite the clinical development and review of drugs intended to treat serious conditions and address unmet medical needs. Drug candidates granted FTD benefit from increased communication with the FDA throughout subsequent drug development, potentially accelerating their clinical development and approval process.

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein))

IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity. The IL-2 arm of IBI363 has been engineered to optimize therapeutic effects with reduced side effects, while the PD-1 binding arm enables PD-1 blockade and selective IL-2 delivery. By simultaneously inhibiting the PD-1/PD-L1 pathway and activating the IL-2 pathway, IBI363 facilitates more precise and efficient targeting and activation of tumor specific T cells. Preclinical studies have shown that IBI363 exhibits strong anti-tumor activity across multiple tumor-bearing pharmacological models, including those resistant to PD-1 inhibitors and metastatic models. Additionally, it has demonstrated a favorable safety profile in preclinical models. Clinical trials are currently underway in China, the United States, and Australia to evaluate its safety, tolerability and preliminary efficacy in subjects with advanced malignancies.

About Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Lung cancer is the most common and deadliest malignancy worldwide, including in China[1], posing a significant public health challenge. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases[2], with squamous cell carcinoma being one of its two major subtypes[2]. In recent years, immune checkpoint inhibitors have transformed the treatment landscape for NSCLC. However, for patients with NSCLC who have failed immunotherapy and lack driver gene mutations, there remains a significant and urgent unmet need for effective treatment options. The standard second- or third-line treatment, docetaxel, offers limited efficacy, with a median progression-free survival (PFS) of less than four months[3],[4]. While antibody-drug conjugates (ADCs) have shown promise, two large Phase 3 studies in squamous NSCLC have yet to demonstrate satisfactory efficacy[3],[4].

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

1 Globocan 2022 (version 1.1) – 08.02.2024

2 NCCN guidelines (NSCLC, version 3.2025)

3 J Clin Oncol . 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544.

4 J Clin Oncol . 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733.

 

CNOOC Limited Announces Buzios7 Project Commences Production

HONG KONG, Feb. 17, 2025 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces that Buzios7 Project has commenced production safely.

Buzios oilfield is located in the Santos Basin, southeast offshore of Brazil, with a water depth of 1,900 to 2,200 meters. It is the largest deep-water pre-salt oilfield in the world. Buzios7 is the sixth project commissioned of the oilfield. It will be developed with an FPSO and subsea production system. 15 development wells are planned to be put into production, including 7 oil producers, 6 water and gas injectors, 1 convertible well and 1 gas injector. With Buzios7 on-stream, Buzios oilfield is expected to produce up to 1 million barrels of crude oil per day in the second half of 2025.

The FPSO used in Buzios7 project is one of the largest FPSOs in the world, with a processing capacity higher than the industry average. It was converted in China in July 2024 and arrived at the oilfield in October the same year. The FPSO is able to produce up to 225,000 barrels of crude oil, process 12 million cubic meters of natural gas per day and store 1.4 million barrels of crude oil. In addition, it is equipped with closed flare to reduce greenhouse gas emissions, and heat recovery devices to reduce energy consumption.

CNOOC Petroleum Brasil Ltda , a wholly-owned subsidiary of the Company, holds a 7.34% interest in the Buzios Shared Reservoir, while the operator Petrobras holds 88.99%, and CNODC Brasil Petróleo e Gás Ltda holds 3.67%.

— End —

Notes to Editors:

More information about the Company is available at http://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company’s price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: mr@cnooc.com.cn 

Mr. Bunny Lee
Porda Havas International Finance Communications Group
Tel: +852 3150 6707
Fax: +852 3150 6728
E-mail: cnooc.hk@pordahavas.com 

EcoFlow Launches DELTA 3 Plus and RIVER 3 Plus in Australia

SYDNEY, Feb. 17, 2025 /PRNewswire/ — EcoFlow is introducing two new portable power solutions, designed to give Australians flexible, innovative and reliable energy for every situation. The EcoFlow DELTA 3 Plus is a dependable home power backup solution that you can also take anywhere, from RVs and caravans to tents and outdoor adventures. The EcoFlow RIVER 3 Plus is a lightweight, easy-to-carry power station built for entry-level users who need a steady source of power while camping, on road trips, or driving across the country. With a simple design and consistent powerful performance, these new solutions ensure Australians stay powered.

As Australians embrace the outdoors more than ever – taking over 15 million caravan and camping trips in 2023 – and with extreme weather events causing more frequent power outages, the need for available, portable power has never been greater. Whether preparing for blackouts due to the forces of mother nature, or staying powered off-grid, EcoFlow’s new products offer flexible energy solutions to meet the needs of Australians today.

Key product features:

EcoFlow DELTA 3 Plus:

Fast charging, powerful output and worry-free endurance. EcoFlow DELTA 3 is a reliable home power backup solution.
Fast charging, powerful output and worry-free endurance. EcoFlow DELTA 3 is a reliable home power backup solution.

  • Fast charging with a capacity of 1024kWH and 1800W output. For example, a 30-minute charge from an AC wall socket can provide enough backup power for a typical refrigerator for at least five hours.
  • Powerful output and ultra-quiet operation. With 11 outport ports, it can continuously power appliances up to 2400W, such as ovens, hair dryers and kettles – perfect for RVs, 4WD trips and home backup power. It runs quietly at just 30db; when using less than 600W, it blends into the background, making it virtually unnoticeable – ideal for use in a tent without disturbing sleep.
  • Compact design and portable. It is more portable compared to its predecessor, weighing 12.5kg. The weight is approximately equal to that of a family tent for two to three people.

EcoFlow RIVER 3 Plus:

Compact, 10ms professional uninterrupted power supply and fast charging. The EcoFlow RIVER 3 Plus is built for entry-level users.
Compact, 10ms professional uninterrupted power supply and fast charging. The EcoFlow RIVER 3 Plus is built for entry-level users.

  • Compact and long-lasting runtime. Weighing only 4.7kg, it is designed to be taken anywhere that needs quick and reliable power. It also offers a 286Wh capacity, which can power your Wi-Fi router up to 35 hours.
  • Fast-charging with multiple charging methods. Traditional home UPS batteries often take eight hours or more to recharge and usually only support AC charging. With its fast charge technology, it significantly reduces AC charging time to just one hour, without damaging the battery. It also supports many charging options, including solar, car and generator.
  • 10ms UPS capability. In an event of a power outage, it can prevent issues like food spoilage from fridge shutdowns, or data loss from sudden computer failures, ensuring essential devices stay powered without interruption.

Both the EcoFlow DELTA 3 Plus and EcoFlow RIVER 3 Plus are available from today via the EcoFlow Australia website, eBay Australia and Amazon Australia.  

The EcoFlow DELTA 3 Plus is $1,599 and the EcoFlow RIVER 3 Plus is $499.

Earlier this month, EcoFlow also launched EcoFlow RIVER 3 (UPS). Its ultra-fast UPS makes it the perfect companion for outdoor adventures.

Images and more information can be found in the below respective media kits.  

About EcoFlow 

EcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 4.5 million users in 140 markets worldwide. For more information, visit https://www.ecoflow.com/au

Media Contact
Allison Worldwide for EcoFlow Australia 
ecoflowanz@allisonworldwide.com  

Navi Medical Technologies’ Neonav® ECG Tip Location System Receives FDA 510(k) Clearance

Revolutionising Vascular Access Care for Critically Ill Newborns and Children

Key Points:

  • FDA 510(k) Clearance Neonav® ECG Tip Location System is now FDA-cleared, enabling its use in U.S. hospitals to enhance pediatric vascular access care.
  • First-of-its-kind Innovation: Neonav® is the only system designed specifically for neonatal and pediatric patients, using real-time ECG signal analysis to ensure accurate placement of Central Venous Access Devices (CVADs), significantly reducing risks like misplacement and migration.
  • U.S. Market Expansion: With clearance secured, and offices in Australia and the United States, Navi Medical Technologies plans to raise capital and engage hospital networks to bring Neonav® to U.S. healthcare providers.
  • Australian Innovation on the Global Stage: Based in Melbourne, Navi is demonstrating how Australian medtech can revolutionize global pediatric care.

MELBOURNE, Australia, Feb. 17, 2025 /PRNewswire/ — Navi Medical Technologies, a medical device company focused on pediatric healthcare innovation, proudly announces that its Neonav® ECG Tip Location System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

This milestone represents a significant step forward in vascular access care for critically ill newborns and children worldwide. The Neonav® is the first medical device of its kind specifically designed for neonatal and pediatric care. By using real-time ECG signal analysis, it aids accurate placement of Central Venous Access Devices (CVADs), significantly reducing the risks associated with misplacement and migration which can cost US hospitals up to USD$1 Billion per year. This breakthrough innovation minimises reliance on confirmatory chest X-rays, will help in reducing delays in care, as well as lowering unintended complications for vulnerable patients.

World-First Technology Tailored for Pediatric Patients

The Neonav® system has the broadest ‘Indication For Use’ of any tip location system on the market, covering preterm newborns through to adults. Importantly, the system can be used to place tiny 1Fr catheters used in very small newborns, and is cleared for placement of catheters both above and below the heart. The system has also been developed to enable ongoing surveillance of catheters after the initial placement, an important first which can help to prevent potentially serious healthcare complications resulting from undiagnosed movement of the tip of the catheter. These novel features address critical challenges faced by healthcare professionals in neonatal and pediatric care.

Dr Janene Fuerch is a Neonatologist at Stanford Children’s Health, and is excited about the prospect of the Neonav being available to assist with the treatment of  children in the United States, “Central lines are lifesaving but can be challenging to position. We need a guidance system to tell us when we are in the correct location. The Neonav system fulfills that need and gives a characteristically blind procedure a way to move forward, telling you exactly where you are and how to move into the correct position”

Strategic Growth & U.S. Expansion

With FDA clearance secured, and offices in Australian and the United States, Navi Medical Technologies will seek to raise capital later this year to support its entry into the U.S. market, “We recognize the tremendous opportunity to bring our ground-breaking technology to the U.S., and we will continue to engage hospital networks and potential partners that can help ensure that our innovations reach the patients who need them most” said Alex Newton, CEO of Navi.

“With FDA clearance in hand, we’re uniquely positioned to drive significant impact in the largest healthcare market in the world. Our investors have the chance to be part of a mission that’s not only financially rewarding but also deeply meaningful. By working together, we can ensure that every critically ill child has access to safer, faster, and more effective care.”

Backed by Leading Healthcare Innovators & Partners

Navi Medical Technologies acknowledges the invaluable support of its investors and partners, including Breakthrough Victoria, The Royal Women’s Hospital, the Australian Federal and Victorian Governments, MTPConnect, and the US FDA Pediatric Device Consortia program. Their backing has been instrumental in achieving this milestone and advancing Navi’s mission to improve pediatric healthcare worldwide.

“We wouldn’t be here without the backing of our investors and partners,” said Alex. “Their support and belief in our vision has enabled us to reach this point and set the stage for global expansion. We’re deeply grateful for their ongoing commitment to innovation and healthcare improvement.”

An Australian Success Story

The FDA clearance highlights Australia’s thriving medtech sector. Minister for Economic Growth and Jobs Danny Pearson celebrated the achievement:

“This local Victorian company will be taking its home-grown technology to the United States – helping make hospital care safer for critically ill newborn babies on the other side of the world.”

Victoria is the medical research capital of Australia – this is a booming industry that is backing economic growth and quality advanced manufacturing jobs across our state.”

Breakthrough Victoria, an investor in Navi, also praised the company’s progress. CEO Rod Bristow commented: “As an investor, we are excited about Navi’s trajectory and its potential to become a leader in the paediatric medical device market. With strong fundamentals, regulatory validation, and a clear pathway to commercialisation, Navi represents a compelling investment opportunity with both financial and wider societal impact.”

About Navi Medical Technologies

Navi Medical Technologies is a Melbourne-based medtech company dedicated to advancing pediatric healthcare. By collaborating with leading clinicians, Navi develops breakthrough technologies that improve outcomes for the most vulnerable patients.

Email: info@navitechnologies.com 
Website: www.navitechnologies.com

Documentary A Bite of China (Season 4) Sparks Discussion: Cultural Ripples from Culinary Encounters

BEIJING, CHINA – Media OutReach Newswire – 15 February 2025 – Cultural exchange has become an essential bridge for communication between nations. Recently, products associated with China, such as the AI technology DeepSeek, the animated film Ne Zha 2, and the food documentary A Bite of China (Season 4), have converged to create a powerful wave of “Chinese style” that is making waves across the globe. Among these, A Bite of China (Season 4) has opened the taste buds of global audiences, allowing them to explore Chinese culture through the universal topic of food. As the documentary gains popularity, a series of visually stunning short videos have gone viral on major social media platforms, attracting media attention and coverage from countries and regions including Portugal, Canada, Japan, South Korea, South Africa, Italy, Dubai, Greece, and Peru.

For a long time, Chinese cuisine abroad has been stereotyped as “convenient,” “takeout,” and “sweet and sour.” However, A Bite of China (Season 4) uses exquisite cinematography to reveal the rich stories and Eastern philosophy behind Chinese food. From its journey across the seas to local adaptations and deep integration with foreign cuisines, Chinese food has sparked cultural ripples, blending and merging with other culinary traditions worldwide.

One particularly striking scene in the documentary shows a street in Paris, where blonde-haired, blue-eyed diners shout “Dao Xiao Mian” (knife-cut noodles) in Chinese. Meanwhile, a Chinese woman in a food truck skillfully slices dough into leaf-like noodles with a curved knife, dropping them into a bubbling pot. This traditional Chinese noodle dish, with its “Chinese kung fu” of kneading and resting, allows French diners to experience authentic Eastern craftsmanship passed down through millennia. One viewer commented on social media, “Watching Chinese chefs cook is like watching a spectacular performance; their hands seem magical, transforming ordinary ingredients into delicious dishes in no time.”

In addition to the authentic journey of Chinese cuisine, Chinese food culture is taking root in various corners of the world, blending and coexisting with local culinary traditions. Southeast Asia’s Nyonya cuisine reflects the wisdom and aesthetic of Chinese dining, with each flavor echoing the Chinese community’s longing for the tastes of their homeland. Michelin-starred chef Adeline in France showcases her “Sino-French fusion” philosophy by using a Chinese wok to prepare the famous French dish bouillabaisse, replacing frying pans with steamers for foie gras, and incorporating Shaoxing wine, a Chinese flower wine, into a white sauce. She also uses Zhenjiang vinegar paired with cinnamon to create a black vinegar sauce. Familiar ingredients, yet unfamiliar flavors, allow French diners to enjoy a delightful culinary experience.

As the world collectively celebrates the first Spring Festival following its successful application for UNESCO recognition, the popularity of A Bite of China (Season 4) is ushering in a new wave of global interest in Chinese cuisine. Foreign viewers are experiencing the vibrant atmosphere of the Spring Festival and the diversity of Chinese food culture, with comments such as, “I used to only know General Tso’s chicken and Mapo tofu, but after watching the documentary, I realized how vast the world of Chinese cuisine is. I want to visit a Chinese restaurant during the Spring Festival to try more delicious dishes.”

The fusion of Chinese and foreign cuisines is not limited to restaurants; it has also permeated the daily lives of ordinary people. In traditional markets in France, Chinese vinegar is displayed alongside Italian balsamic vinegar; in various Southeast Asian countries, Chinese restaurants are transforming from “exclusive to Chinese” to “national cuisine”; in American classrooms, Chinese cuisine has become a subject for global students to understand and learn.

At the same time, China is welcoming the world with a more open attitude. Recent visa facilitation policies for foreigners have made it fashionable to “check in” on Chinese customs and traditions. The airing of A Bite of China (Season 4) will undoubtedly spark more interest among foreigners in Chinese cuisine, encouraging them to experience this land firsthand—tasting freshly made jianbing (Chinese crepes) in the alleys, savoring West Lake vinegar fish in the waters of Jiangnan, and feeling the heat of spicy hotpot in the streets of Sichuan and Chongqing.

As the documentary states, “If there truly exists a clear culinary map of the world, it certainly would not have clear national borders.” When French diners pick up knife-cut noodles with chopsticks, when Silicon Valley elites have Shanghai wontons on their plates, and when the British public falls in love with “spicy” and “fish fragrant” flavors, they are not just tasting a symphony created by Chinese cooking techniques; they are experiencing the passion of an ancient civilization for life.

Hashtag: #ABiteofChina

The issuer is solely responsible for the content of this announcement.